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ABSTRACT
Objectives: Persistent environmental pollutants,
including heavy metals and persistent organic
pollutants (POPs), have a ubiquitous presence. Many
of these pollutants affect neurobiological processes,
either accidentally or by design. The aim of this study
was to explore the associations between assayed
measures of POPs and heavy metals and depressive
symptoms. We hypothesised that higher levels of
pollutants and metals would be associated with
depressive symptoms.
Setting: National Health and Nutrition Examination
Survey (NHANES).
Participants: A total of 15 140 eligible people were
included across the three examined waves of NHANES.
Primary and secondary outcome measures:
Depressive symptoms were assessed using the nine-
item version of the Patient Health Questionnaire (PHQ-
9), using a cut-off point of 9/10 as likely depression
cases. Organic pollutants and heavy metals, including
cadmium, lead and mercury, as well as polyfluorinated
compounds (PFCs), pesticides, phenols and
phthalates, were measured in blood or urine.
Results: Higher cadmium was positively associated
with depression (adjusted Prevalence Ratios (PR)
=1.48, 95% CI 1.16 to 1.90). Higher levels of mercury
were negatively associated with depression (adjusted
PR=0.62, 95% CI 0.50 to 0.78), and mercury was
associated with increased fish consumption (n=5500,
r=0.366, p<0.001). In addition, several PFCs
(perfluorooctanoic acid, perfluorohexane sulfonic acid,
perfluorodecanoic acid and perfluorononanoic acid)
were negatively associated with the prevalence of
depression.
Conclusions: Cadmium was associated with an
increased likelihood of depression. Contrary to
hypotheses, many of persistent environmental
pollutants were not associated or negatively associated
with depression. While the inverse association between
mercury and depressive symptoms may be explained
by a protective role for fish consumption, the negative
associations with other pollutants remains unclear.
This exploratory study suggests the need for further
investigation of the role of various agents and classes
of agents in the pathophysiology of depression.
BACKGROUND
Persistent environmental pollutants have a
ubiquitous presence. Such environmental
pollutants include the inorganic heavy
metals and persistent organic pollutants
(POPs). Easily transported by wind and
water, these pollutants are found across the
globe, often far from their original source.1–4
While many POPs (eg, pesticides) were expli-
citly designed to have bioactive properties,
the bioactive effects of many compounds
were only discovered subsequent to their
development and use.5–7
Many environmental pollutants are known
to exert signiﬁcant impacts on human health
in a dose-dependent fashion. POPs, due to
Strengths and limitations of this study
▪ Strengths of this study include the quality and
size of the National Health and Nutrition
Examination Survey (NHANES) database and the
rigour of its measures.
▪ Owing to the vast number of potential persistent
organic pollutants, we did not have the ability to
assess all agents of relevance.
▪ Owing to the exploratory nature of this analysis
and the absence of a singular a-priori target, the
potential for type 1 errors should be noted.
▪ It is unclear if these data represent true neuro-
biological effects, or are proxy markers of
residual confounding due to other operative
variables.
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their potential to bioaccumulate and biomagnify in
human and animal tissues, appear to become progres-
sively concentrated up the food chain.8 POPs have docu-
mented adverse effects on a diversity of biological
systems, and extensive exposure can cause illness and
death. They can disrupt endocrine, reproductive and
immune systems, are associated with risk for cancer and,
germane to this report, are linked to neurobehavioural
disorders. As an exemplar, in a recent study evaluating
the neurotoxic effects of POPs, a Spanish birth cohort
demonstrated that prenatal exposure to polychlorinated
biphenyl-153 is associated with worse psychomotor devel-
opment, supporting the importance of understanding
how POPs interfere in brain development, in order to
guide and develop environmental strategies to minimise
the impact on brain health.9
Other POPs also exert effects on neuronal systems in
preclinical models. Neurotoxic effects of hexachlorocy-
clohexane pesticides have been reported in animals
after ingestion of a single dose, while prolonged expos-
ure to low doses in rats resulted in signiﬁcantly altered
Skinner box behaviour (operant conditioning), and
reduced nerve conduction velocity.10 11 Polychlorinated
dibenzo-p-dioxins and polychlorinated dibenzofurans,
frequently referred to as ‘dioxins’, are associated with
neurodevelopmental delays and subtle neurobehavioural
effects, including neonatal hypotonia.12 Bisphenol A
(BPA), used in the lining of food containers, is impli-
cated in neuroendocrine and developmental abnormal-
ities.13 Neurobehavioural effects following perinatal
exposure are reported in animals (monkey, rat and
mouse) and humans.14 In rhesus monkey infants
exposed in utero and during lactation, impaired learn-
ing ability and hyperactivity were reported.12
Some previous studies have investigated the relation-
ship between exposure to environmental pollutants and
neurobehavioural effects in humans. One study reported
that solvent exposure was linked to an increased risk of
anxiety and depressive disorders in adults.15 In another
cohort study of 1512 participants, prenatal and early
childhood tetrachloroethylene contaminated drinking
water exposure was associated with an increased risk of
bipolar disorder, post-traumatic stress disorder and
schizophrenia.16 Exposure to organophosphate pesti-
cides in farmers was linked to higher levels of somatisa-
tion, as well as higher blood levels of superoxide
dismutase and lipid peroxidation and lowered total anti-
oxidant capacity.17 This may be germane to psychiatric
health due to the demonstrated role of oxidative stress
in a number of psychiatric disorders.18 19 Data also have
linked heavy metal exposure to mood disorders.
Symptoms of manganese poisoning can include
euphoria, apathy, hallucinations, ﬂight of ideas, compul-
sivity agitation and verbosity; and symptoms of mercury
poisoning can include irritability, poor concentration,
memory deﬁciencies, anxiety and depression.20 21 In two
selected samples with a psychotic disorder or bipolar dis-
order, blood levels of cadmium and lead were found to
be higher than in healthy control participants. Although
very limited in scope, these data point to a possible
impact of these pollutants in mental health.22 23 Heavy
metals such as cadmium, arsenic and lead are found in
cigarettes, and this may be one of the multitudes of
pathways whereby smoking may be detrimental to
health.24
An understanding of which pollutants, if any, can
affect the development of depressive symptoms is
imperative given the widespread use of these pollutants
and the substantial burden of disease imposed by uni-
polar depression.25 The aim of this study, therefore, was
to explore the associations between numerous assayed
measures of POPs and heavy metals and depressive
symptoms in the National Health and Nutrition
Examination Survey (NHANES). We hypothesised posi-
tive relationships between POPs and heavy metals and
depression.
METHODS
Participants
This study included adults who participated in one
of the three latter waves (2005–2006, 2007–2008 and
2009–2010) of the NHANES, for which data is publicly
available (http://www.cdc.gov/nchs/nhanes.htm). Of a
sample of 18 318 individuals who participated in one of
the three waves and were aged over 18 years, those who
did not have a valid depression screen were excluded
from the analyses, resulting in a sample of 15 760. The
maximum sample size for analyses including missing
data on pollutants was 15 140 participants. For total
sample size according to class of pollutant see table 1.
Measurements
The outcome, depressive symptoms, was assessed using
the nine-item depression module of the Patient Health
Questionnaire (PHQ-9). The PHQ-9 is based on the
Diagnostic and Statistical Manual of Mental Disorders
Fourth Edition (DSM-IV) criteria for major depressive
disorder and has been considered to be reliable and
valid for use in the general population.26 To indicate the
presence of signiﬁcant depressive symptoms we
employed a cut-off point of 9/10.27 This is largely recog-
nised as the optimal trade-off between sensitivity and
speciﬁcity.28
The exposures of interest included the following:
Heavy metals
Blood lead, cadmium and mercury were assessed in all
three waves (n=16 691). Whole blood lead (Pb),
cadmium (Cd) and mercury (Hg) concentrations were
determined using inductively coupled plasma mass spec-
trometry.29–31
Polyfluorinated compounds
Levels of polyﬂuorinated compounds (PFCs) were mea-
sured in subsamples drawn from each of the three waves
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(n=5442). The quantitative detection of perﬂuorooctane
sulfonamide (PFOSA), 2-(N-methyl-perﬂuorooctanesul-
fonamido) acetic acid (Me-PFOSA-AcOH), 2-(N-ethyl-
perﬂuorooctanesulfonamido) acetic acid (Et-PFOSA-
AcOH), perﬂuorobutanesulfonate (PFBuS), perﬂuoro-
hexanesulfonate (PFHxS), perﬂuorooctanesulfonate
(PFOS), perﬂuoroheptanoate (PFHpA), perﬂuorooc-
tanoate (PFOA), perﬂuorononanoate (PFNA), perﬂuor-
odecanoate (PFDeA), perﬂuoroundecanoate (PFUA),
and perﬂuorododecanoate in serum was performed
using solid phase extraction (SPE) coupled to high-
performance liquid chromatography (HPLC)—turbo
ion spray ionisation (TIS)—tandem mass spectrometry
(MS/MS; online SPE-HPLC-TIS-MS/MS).29–31
Environmental pesticides and phenols
Urinary levels of pesticides and phenols were measured
in subsamples drawn from each of the three waves
(n=5588). The method employed SPE coupled online to
HPLC and MS/MS for measuring phenols and pesti-
cides. With the use of isotopically labelled internal stan-
dards, the sensitivity is sufﬁcient for measuring urinary
levels of phenols in non-occupationally exposed partici-
pants.29–31
Phthalates
Urinary phthalates were measured in subsamples drawn
from the ﬁrst two waves (n=3566). The test utilises HPLC
—electrospray ionisation (ESI)—MS/MS (HPLC-ESI-MS/
MS) for the quantitative detection of the following meta-
bolites: monomethyl phthalate (mMP), monoethyl phthal-
ate (mEP), monobutyl phthalate (mBP), mono-isobutyl
phthalate (miBP), mono-(3-carboxypropyl) phthalate
(mCPP), monocyclohexyl phthalate (mCHP), mono-(2-
ethylhexyl) phthalate (mEHP), monooctyl phthalate
(mOP), monobenzyl phthalate (mBzP), monoisononyl
phthalate (mNP), mono-(2-ethyl-5-oxohexyl) phthalate
(mEOHP), mono-(2-ethyl-5-hydroxyhexyl) phthalate
(mEHHP), mono-(2-ethyl-5-carboxypentyl) phthalate
(mECPP), monocarboxyoctyl phthalate (MCOP) and
monocarboxynonyl phthalate (MCNP). Samples were
then processed using enzymatic deconjugation of the glu-
curonidated phthalate monoesters followed by online SPE
coupled with reversed HPLC-ESI-MS/MS.29–31
Organophosphates
Urinary organophosphates were measured in a sub-
sample drawn from the 2007–2008 wave (n=2593). Urine
samples were spiked with stable isotope analogues of the
dialkyl phosphate (DAPs) metabolites and water was
removed from the samples. The dried residue was dis-
solved in acetonitrile and diethyl ether, and the DAPs
were chemically derivatised to their respective chloro-
propyl phosphate esters. The chloropropyl phosphate
esters were concentrated, and analysed using gas chro-
matography—MS/MS (GC–MS/MS).29–31
Other exposures, such as demographic and socio-
economic characteristics, medical conditions, relevant
biological measures and other lifestyle factors were avail-
able from the three mentioned waves of data collection.
Income was documented and divided into four categor-
ies (less than US$10 000/year, US$10 000–US$25 000,
US$25 000–US$45 000 and over US$45 000). The
poverty index ratio (PIR) is based on the number of
family members and annual family income, calculated
using poverty thresholds provided by the US Census
Bureau.32 It was divided in quartiles as a further control
variable. Country of birth and ethnicity was documented
and grouped as USA versus other and Caucasian,
Hispanic, African-American and other, respectively.
Chronic medical conditions including cardiovascular
and thyroid conditions, asthma, arthritis, liver disease,
chronic obstructive pulmonary disease and cancer were
self-reported. Smoking was assessed with a biomarker of
smoke exposure, serum cotinine levels,33 which allow for
the additional control of secondhand smoke; it was also
categorised in quartiles. Biological measurements com-
prised creatinine, cholesterol and glucose serum levels.
Fish consumption was estimated at the 2005–2006 wave
of data collection by Food Frequency Questionnaire.34
We included this variable due to mercury accumulation
in some ﬁsh species.
Statistical analysis
The three continuous waves of NHANES were combined
according to the Centre for Disease Control and
Prevention (CDC) instructions to achieve maximum stat-
istical power.29–31 Multivariate models were developed to
identify factors associated with the presence of signiﬁ-
cant depressive symptoms, incorporating potential con-
founders including socioeconomic status, ethnicity,
comorbid medical illnesses and relevant biological mea-
surements. We conducted four different hierarchical
models; unadjusted; adjusted for income, the PIR,
country of birth, ethnicity, gender and age bands (cate-
gorised in 10-year bins; Model 1), the latter plus medical
Table 1 Sample sizes for different classes of pollutants measured in the three NHANES waves assessed
NHANES
wave
Heavy metals
(blood)
PFCs
(blood)
Pesticides
(urine)
Phthalates
(urine)
Phenols
(urine)
Organophosphate
(urine)
2005–2006 4608 1513 1521 1521 1521 NA
2007–2008 5172 1689 1767 1767 1767 1753
2009–2010 5360 1726 1789 NA 1789 NA
NA, not applicable; NHANES, National Health and Nutrition Examination Survey.
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conditions and smoking exposure (Model 2) and all
plus biological measures (Model 3). Prevalence ratios
(PR) for depression were calculated using binary
Poisson regression with robust estimation of SEs.35
Furthermore, Spearman rank correlation was used to
test the association between mercury and total ﬁsh con-
sumption levels. The distribution of measured pollutants
were extremely skewed, therefore the data were cate-
gorised into quartiles, as in previous manuscripts based
on NHANES data.36–39
RESULTS
The prevalence of likely depression, adjusted for the
sample design was 7.1% (5.4% in the 2005–2006 wave,
8.1% in the 2007–2008 wave and 7.7% in the 2009–2010
wave). Characteristics for the whole group and those
with and without depression are shown in table 2.
Table 3 shows associations between blood heavy metals
and depression. Serum cadmium was associated with a
higher prevalence of depression (adjusted (Adj)
PR=1.48, 95% CI 1.16 to 1.90) after adjustment for con-
founders. There was no association between depression
and lead. Mercury was associated with a lower preva-
lence of depression (Adj PR=0.62, 95% CI 0.50 to 0.78).
Frequency of ﬁsh consumption was associated with total
circulating mercury (n=5500, r=0.366, p<0.001).
Several PFCs (table 4) were associated with a lower
prevalence of depression; perﬂuorooctanoic acid (Adj
PR=0.63, 95% CI 0.44 to 0.89), perﬂuorohexane sulfonic
acid (Adj PR=0.67, 95% CI 0.49 to 0.92), perﬂuorodeca-
noic acid (Adj PR=0.62, 95% CI 0.45 to 0.86) and per-
ﬂuorononanoic acid (Adj PR=0.63, 95% CI 0.43 to
0.92). With the exception of the phenols,
benzophenone-3 (Adj PR=0.55, 95% CI 0.34 to 0.88), tri-
closan (Adj PR=0.66, 95% CI 0.47 to 0.93) and ethyl
paraben (Adj PR=0.76, 95% CI 0.57 to 1.00), there were
no associations between the phthalates, pesticides and
organophosphates and depression (tables 4–6).
DISCUSSION
In this study, cadmium was associated with an increased
likelihood of depression. However, contrary to our
hypothesis, other heavy metals and POPs demonstrated
either no association or negative associations with likely
depression.
Heavy metals are very well-established neurotoxins,
with extensive data on mercury, lead and other agents.
They can interfere with major cellular systems at levels
well below those causing classic signs of toxicity.40 41
Cadmium induces neurotoxicity via multiple pathways,
including interference with the blood–brain barrier,
increases in oxidative stress, interference with zinc and
calcium-dependent processes and metallothionein and
induction of apoptosis. Intriguingly, many of these path-
ways are now known to be intimately involved in the
pathophysiology of mood disorders.42 Cadmium ions
bind to mitochondria and can inhibit respiration and
oxidative phosphorylation.40 Furthermore, cadmium has
been associated with synaptic malfunction through
attenuation of Na(+)-dependent glutamate uptake and
blockage of voltage-gated Ca(2+).43 It is worth mention-
ing that ketamine, a N-methyl-D-aspartate receptor
antagonist that, in turn, increases presynaptic glutamate
release, has emerged as a new drug for depression treat-
ment.44 Similarly, lead impacts many pathways known to
be operative in the genesis of depression, including
neurogenesis and apoptosis, oxidative stress and glutathi-
one, glutamate, calcium and calmodulin and neuro-
transmitters such as acetylcholine.18 19 45 46 In one study
examining mental health in individuals exposed via
Table 2 Characteristics of the sample divided for the presence of significant depressive symptoms (PHQ9>9)
No depressive symptoms Depressive symptoms Total sample
Female sex (%) 49.6 63.7 50.8
Age* 46 (31–63) 46 (33–58) 46 (31–63)
Non-Caucasian ethnicity (%) 51.8 57.3 52.2
Born outside USA (%) 24.9 18.1 24.3
Yearly family income over 45k (%) 44.9 23.5 43.1
Cardiovascular illness (%) 9.8 17.8 10.5
Chronic obstructive pulmonary disease (%) 6.3 17.4 7.3
Cancer (%) 9.3 11 9.5
Liver disease (%) 3 7.7 3.4
Arthritis (%) 26.3 43.2 27.8
Asthma (%) 12.9 23.3 13.8
Thyroid disease (%) 9 14.9 9.5
Family PIR* 2.27 (1.17–4.18) 1.23 (0.73–2.27) 1.82 (0.96–3.60)
Cholesterol levels* 192 (166–221) 193 (166–224) 191 (165–221)
Creatinine levels* 0.87 (0.72–1.01) 0.80 (0.70–0.97) 0.85 (0.72–1.00)
Glucose levels* 92 (84–103) 93 (85–106) 92 (84–103)
*Continuous measures shown as median (IQR).
PHQ-9, nine-item depression module of the Patient Health Questionnaire; PIR, poverty index ratio.
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mining to heavy metals, including cadmium, zinc, lead
and copper, higher total scale scores on the Symptom
Checklist 90 (SCL-90) were seen in the exposed com-
pared with the control group, and ratings on somatisa-
tion, obsessive–compulsive, interpersonal sensitivity,
depression, anxiety, hostility, paranoid ideation, psychoti-
cism and other symptoms were higher in the exposed
individuals.47 In a clinical study, higher levels of
cadmium and lead were found in individuals with
depression, and higher levels of lead in those with
schizophrenia.48 Lower selenium is linked to depression
risk.49
Contrary to expectations, mercury was inversely corre-
lated with depression in our study. This ﬁnding requires
replication and further exploration, as this relationship
may be secondary to other factors associated with
mercury consumption. It is thought that mercury con-
sumption may be a proxy of seafood consumption,
which may itself be the operative factor, or may be a
proxy of factors such as socioeconomic status and omega
3 intake.8 50 Thus, the protective effect of ﬁsh consump-
tion, which has been shown to be associated with
reduced depression risk, may outweigh any potential
negative contribution of mercury to depression
prevalence.51
That several PFCs were associated with a lower risk of
depression was an unexpected ﬁnding, given many of
these compounds have shown signiﬁcant neurodevelop-
mental effects.52 Perﬂuorooctanoic acid belongs to the
family of perﬂuorinated compounds, which are used
extensively in industrial and consumer applications,
including food packaging, clothing, fabrics and carpets.
They are ubiquitous in the environment, being found in
dust and human milk. Prenatal exposure is linked to
developmental sequelae.53 Perﬂuorooctanoic acid also
alters brain proteins including CaMKII, GAP-43 and
synaptophysin that have critical roles in neuronal growth
and synaptogenesis.54 Prenatal exposure results in neu-
robehavoural deﬁcits in adult mice, including hyperactiv-
ity, altered spontaneous behaviour and impaired
habituation, features found in many primary psychiatric
disorders.55 These effects were shown to worsen with
age.
Moreover, perﬂuorooctane sulfonic acid perturbs the
functioning of motor neurones by altering α-Tubulin
and proliferating cell nuclear antigen.56 It also induces
Table 3 Prevalence ratios for upper quartile (with first quartile used as reference) for multivariate associations between
blood heavy metals and depression
Unadjusted Model 1* Model 2† Model 3‡
n=15 140 n=14 016 n=12 807 n=12 746
Cadmium 2.40 (1.93 to 3.00) 1.89 (1.49 to 2.40) 1.49 (1.16 to 1.91) 1.48 (1.16 to 1.90)
Lead 0.95 (0.81 to 1.13) 0.98 (0.78 to 1.25) 0.79 (0.62 to 1.00) 0.81 (0.64 to 1.02)
Mercury 0.45 (0.36 to 0.56) 0.56 (0.45 to 0.70) 0.62 (0.50 to 0.78) 0.62 (0.50 to 0.78)
*Adjusted for demographics and socioeconomic status (age, sex, poverty, family income, ethnicity and country of birth).
†Adjusted for the above, cotinine levels and chronic medical illness.
‡Adjusted for the above and blood levels of cholesterol, glucose and creatinine.
Table 4 Prevalence ratios for upper quartile (with first quartile used as reference) for multivariate associations between
blood polyfluorinated compounds and depression
Unadjusted Model 1* Model 2† Model 3‡
n=5026 n=4645 n=4272 n=4266
Perfluorooctanoic acid 0.49 (0.33 to 0.71) 0.66 (0.46 to 0.93) 0.61 (0.43 to 0.0.87) 0.63 (0.44 to 0.89)
Perfluorohexane sulfonic acid 0.49 (0.36 to 0.66) 0.66 (0.47 to 0.93) 0.66 (0.47 to 0.93) 0.67 (0.49 to 0.92)
2-(N-ethyl-PFOSA) acetate§ 0.62 (0.31 to 1.26) 0.77 (0.39 to 1.50) 0.73 (0.38 to 1.41) 0.72 (0.38 to 1.35)
2-(N-methyl-PFOSA) acetate 0.84 (0.55 to 1.26) 0.94 (0.63 to 1.42) 0.79 (0.55 to 1.28) 0.82 (0.57 to 1.17)
Perfluorodecanoic acid 0.55 (0.40 to 0.75) 0.64 (0.48 to 0.86) 0.62 (0.45 to 0.85) 0.62 (0.45 to 0.86)
Perfluorobutane sulfonic acid¶ 0.89 (0.27 to 2.86) 1.29 (0.45 to 3.70) 1.47 (0.51 to 4.19) 1.50 (0.52 to 4.29)
Perfluoroheptanoic acid§ 0.89 (0.68 to 1.18) 0.62 (0.32 to 1.22) 0.52 (0.24 to 1.11) 0.53 (0.25 to 1.14)
Perfluorononanoic acid 0.61 (0.43 to 0.87) 0.64 (0.41 to 0.99) 0.62 (0.42 to 0.92) 0.63 (0.43 to 0.92)
Perfluorooctane sulfonamide¶ 0.58 (0.37 to 0.90) 0.93 (0.58 to 1.50) 0.89 (0.55 to 1.43) 0.89 (0.54 to 1.45)
Perfluoroundecanoic acid§ 0.60 (0.40 to 0.91) 0.68 (0.44 to 1.05) 0.73 (0.47 to 1.12) 0.72 (0.47 to 1.09)
Perfluorododecanoic acid§ 0.95 (0.69 to 1.30) 0.80 (0.39 to 1.37) 0.80 (0.39 to 1.63) 0.83 (0.41 to 1.69)
Perfluorooctane sulfonic acid 0.52 (0.29 to 0.66) 0.60 (0.34 to 1.05) 0.65 (0.38 to 1.12) 0.68 (0.39 to 1.16)
*Adjusted for demographics and socioeconomic status (age, sex, poverty, family income, ethnicity and country of birth).
†Adjusted for the above, cotinine levels and chronic medical illness.
‡Adjusted for the above and blood levels of cholesterol, glucose and creatinine.
§Only three groups formed because of the lack of granularity in data.
¶Only two groups formed because of the lack of granularity in data.
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brain oxidative stress by dysregulating cyclin-dependant
kinase 5 and peroxiredoxin, and causes an inﬂammatory
glial response.57 It impairs calcium signalling,58 and
interferes with gene transcription related to neuroactive
ligand-receptor interaction, the cell cycle, cell communi-
cation, long-term potentiation and depression, and per-
oxisome proliferator-activated receptor (PPAR)
signalling.59 Neurotoxicity has been shown even after a
Table 5 Prevalence ratios for upper quartile (with first quartile used as reference) for multivariate associations between
urinary phthalates and phenols and depression
Unadjusted Model 1* Model 2† Model 3‡
Phthalates n=3342 n=3117 n=2747 n=2710
Monocarboxynonyl Phthalate 0.91 (0.57 to 1.46) 1.04 (0.68 to 1.59) 0.96 (0.60 to 1.55) 0.93 (0.58 to 1.48)
Monocarboxyoctyl Phthalate 0.91 (0.56 to 1.48) 1.06 (0.69 to 1.63) 1.08 (0.68 to 1.71) 1.05 (0.66 to 1.66)
Mono-2-ethyl-5-carboxypentyl phthalate 0.84 (0.51 to 1.38) 0.89 (0.53 to 1.51) 0.76 (0.42 to 1.35) 0.76 (0.42 to 1.37)
Mono-N-butyl phthalate 1.65 (0.98 to 2.76) 1.35 (0.78 to 2.36) 1.17 (0.63 to 2.17) 1.14 (0.65 to 1.99)
Mono-(3-carboxypropyl) phthalate 1.34 (0.82 to 2.21) 1.45 (0.88 to 2.40) 1.20 (0.67 to 2.13) 1.18 (0.67 to 2.07)
Monoethyl phthalate 1.48 (0.94 to 2.34) 1.26 (0.76 to 2.08) 1.18 (0.72 to 1.96) 1.28 (0.77 to 2.11)
Mono-(2-ethyl-5-hydroxyhexyl) phthalate 0.94 (0.55 to 1.61) 0.96 (0.55 to 1.68) 0.86 (0.46 to 1.59) 0.79 (0.43 to 1.45)
Mono-(2-ethyl)-hexyl phthalate 0.91 (0.50 to 1.63) 0.93 (0.50 to 1.73) 0.94 (0.48 to 1.85) 0.96 (0.49 to 1,87)
Mono-N-methyl phthalate§ 0.86 (0.57 to 1.30) 0.82 (0.56 to 1.20) 0.72 (0.52 to 0.98) 0.73 (0.54 to 1.01)
Mono-isononyl phthalate¶ 1.27 (0.65 to 2.50) 1.45 (0.76 to 2.79) 1.50 (0.73 to 3.06) 1.38 (0.70 to 2.73)
Mono-(2-ethyl-5-oxohexyl) phthalate 0.93 (0.53 to 1.63) 0.99 (0.55 to 1.78) 0.89 (0.45 to 1.78) 0.84 (0.44 to 1.59)
Mono-benzyl phthalate 1.51 (0.85 to 2.69) 1.28 (0.66 to 2.46) 1.02 (0.48 to 2.14) 0.99 (0.52 to 1.88)
Mono-isobutyl phthalate 1.54 (0.88 to 2.69) 1.34 (0.77 to 2.33) 1.13 (0.58 to 2.18) 1.11 (0.60 to 2.06)
Phenols n=5160 n=4775 n=4202 n=4185
Bisphenol A 1.44 (0.98 to 2.10) 1.22 (0.80 to 1.85) 1.00 (0.64 to 1.55) 0.94 (0.60 to 1.46)
Benzophenone-3 0.47 (0.33 to 0.67) 0.54 (0.37 to 0.80) 0.55 (0.34 to 0.88) 0.55 (0.34 to 0.88)
4-tert-octylphenol¶ 1.47 (10.7 to 2.02) 1.35 (0.95 to 1.92) 1.35 (0.94 to 1.95) 1.34 (0.93 to 1.94)
Triclosan 0.52 (0.40 to 0.69) 0.63 (0.47 to 0.84) 0.65 (0.46 to 0.91) 0.66 (0.47 to 0.93)
Butyl paraben§ 1.00 (0.72 to 1.41) 0.92 (0.66 to 1.28) 0.94 (0.66 to 1.34) 0.96 (0.67 to 1.37)
Ethyl paraben§ 0.83 (0.62 to 1.09) 0.74 (0.56 to 0.99) 0.73 (0.55 to 0.97) 0.76 (0.57 to 1.00)
Methy paraben 1.04 (0.73 to 1.48) 0.75 (0.49 to 1.15) 0.77 (0.51 to 1.18) 0.76 (0.50 to 1.14)
Propyl paraben 1.13 (0.87 to 1.64) 0.91 (0.59 to 1.40) 1.03 (0.68 to 1.58) 1.02 (0.67 to 1.54)
*Adjusted for demographics and socioeconomic status (age, sex, poverty, family income, ethnicity and country of birth).
†Adjusted for the above, cotinine levels and chronic medical illness.
‡Adjusted for the above and blood levels of cholesterol, glucose and creatinine.
§Only three groups formed because of the lack of granularity in data.
¶Only two groups formed because of the lack of granularity in data.
Table 6 Prevalence ratios for upper quartile (with first quartile used as reference) for multivariate associations between
urinary organophosphate pesticides and depression
Unadjusted Model 1* Model 2† Model 3‡
Pesticides n=5160 n=4775 n=4202 n=4185
2,5-dichlorophenol 1.76 (1.29 to 2.39) 1.29 (0.90 to 1.85) 1.17 (0.78 to 1.74) 1.18 (0.80 to 1.73)
O-phenyl phenol§ 1.38 (0.97 to 1.97) 1.27 (0.91 to 1.80) 1.21 (0.86 to 1.70) 1.12 (0.80 to 1.56)
2,4-dichlorophenol 1.35 (1.04 to 1.76) 1.10 (0.82 to 1.49) 1.04 (0.74 to 1.46) 1.04 (0.74 to 1.46)
2,4,5-trichlorophenol§ 1.29 (0.92 to 1.80) 1.14 (0.77 to 1.68) 1.08 (0.72 to 1.63) 1.09 (0.72 to 1.66)
2,4,6-trichlorophenol 1.21 (0.82 to 1.77) 1.02 (0.70 to 1.47) 1.01 (0.67 to 1.52) 1.01 (0.67 to 1.52)
Organophosphates n=1785 n=1627 n=1472 n=1465
Dimethylphosphate§ 0.96 (0.53 to 1.74) 1.26 (0.73 to 2.19) 1.20 (0.78 to 1.85) 1.20 (0.77 to 1.86)
Diethylphosphate§ 0.85 (0.51 to 1.42) 0.96 (0.58 to 1.57) 0.99 (0.55 to 1.79) 0.98 (0.55 to 1.75)
Dimethylthiophosphate 0.69 (0.48 to 0.99) 0.89 (0.51 to 1.55) 0.98 (0.52 to 1.83) 1.02 (0.52 to 1.99)
Diethylthiophosphate§ 0.65 (0.41 to 1.01) 0.88 (0.58 to 1.34) 1.07 (0.73 to 1.55) 1.08 (0.76 to 1.55)
Dimethyldithiophosphate¶ 0.81 (0.49 to 1.35) 1.01 (0.65 to 1.57) 1.02 (0.69 to 1.51) 1.01 (0.66 to 1.55)
*Adjusted for demographics and socioeconomic status (age, sex, poverty, family income, ethnicity and country of birth).
†Adjusted for the above, cotinine levels and chronic medical illness.
‡Adjusted for the above and blood levels of cholesterol, glucose and creatinine.
§Only three groups formed because of the lack of granularity in data.
¶Only two groups formed because of the lack of granularity in data.
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single exposure.60 Perﬂuorodecanoic acid stimulated the
proliferation of glioblastoma cell growth, although the
behavioural effects of this agent are unknown.58
Polyﬂuoroalkyl chemicals (PFCs), which are widely
used in consumer products, are associated with diverse
adverse health impacts. There is a report of human
neurotoxic effects of perﬂuorooctane sulfonic acid and
perﬂuorooctanoic acid exposure. Among 1400 pairs of
pregnant women and their offspring who were randomly
selected from the Danish National Birth Cohort, there
was an association between delayed gross motor develop-
ment in infancy and maternal perﬂuorooctane sulfonic
acid levels, although levels were not associated with
delays in other developmental milestones, nor atten-
tion.61 In another epidemiological study, perﬂuorooc-
tane sulfonic acid, perﬂuorooctanoic acid and
perﬂuorohexane sulfonic acid but not perﬂuoronona-
noic acid, exposure was linked to attention deﬁcit hyper-
activity in adolescents.62
There are no published reports on perﬂuoroundeca-
noic acid, 2,5-dichlorophenol or O-phenyl phenol and
the brain or neurotoxicicity. However, BPA is capable of
altering neuronal function via multiple pathways, and
developmental exposure to even low doses of BPA
during development results in impairment of neurobe-
havioural development and results in enduring impacts
on brain structure, function and behaviour in animal
studies. Nanomolar doses of BPA can alter hippocampal
long-term potentiation, resulting in signiﬁcant effects on
memory.63 BPA exposure in animal models results in
hyperactivity, as well as disturbed short-term and long-
term memory with adult or prenatal exposure.64 65 This
can be ameliorated by administration of N-acetyl cyst-
eine.66 There are case reports of BPA exposure and neu-
robehavioural abnormalities in humans, particularly
excitability, lethargy and stress abstinence, associated
with dietary exposure to food heated in plastics.67 In
adolescent inner city children, phthalate exposure was
linked to poorer social cognition, social communication
and social awareness.68 BPA exposure has been puta-
tively linked to schizophrenia.69 A relationship between
increased hyperactivity and aggression in 2-year olds and
prenatal BPA exposure has been suggested.70 For these
reasons, we had hypothesised a positive relationship
between these agents and depression; however, these
relationships were not observed and, indeed, the inverse
was observed in many instances. It is not clear why this
may be the case.
This study has many strengths but also some limita-
tions. The strengths of this study include the quality and
size of the NHANES database and the rigour of its mea-
sures. However, given the vast number of potential
POPS, we did not have the ability to assess all agents of
relevance. Moreover, given the exploratory nature of this
analysis and the absence of a singular a-priori target, the
potential for type 1 errors should be noted. It also
remains to be clariﬁed if these data represent true
neurobiological effects, or are proxy markers of other
operative variables. Different pollutants have a tendency
to cluster differently with important socioeconomic vari-
ables. Pesticides, for instance, are associated with a lower
income.71 PFCs, which come from domestic utensils, are
associated with the higher end of the income spectrum.
This was nicely demonstrated in our analysis. Although
we attempted to control for such effects, we cannot
exclude that residual confounding is ultimately respon-
sible for the associations we found between PFCs and
depression.72
CONCLUSION
In this large, population-based study of adults, cadmium
levels were positively associated with depression; however,
other investigated POPs and heavy metals were either not
associated or inversely associated with depression. This
was in contrast to our hypotheses and the explanation for
these negative ﬁndings remains uncertain. Nevertheless,
this study provides tantalising clues about agents and
classes of agents requiring closer analysis.
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